La maladie de Parkinson en France (serveur d'exploration) - Analysis (USA)

Index « Auteurs » - entrée « Laurence Salin »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Laurence Richard < Laurence Salin < Laurent Bezin  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000453 (2010) Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
000466 (2010) Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
000619 (2007) Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (Tesofensine) in early parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
3Nervous system diseases
3Parkinson disease
2Dopamine agonist
2Parkinson's disease
2Pramipexole
2Release
2Treatment
2dopamine agonist
1Aged
1Antiparkinson Agents (administration & dosage)
1Antiparkinson Agents (adverse effects)
1Benzothiazoles (administration & dosage)
1Benzothiazoles (adverse effects)
1Clinical trial
1Confidence Intervals
1Delayed-Action Preparations (therapeutic use)
1Dopamine
1Dose-Response Relationship, Drug
1Double-Blind Method
1Drug Administration Schedule
1Evaluation
1Female
1Humans
1Male
1Middle Aged
1Parkinson Disease (drug therapy)
1Reuptake inhibitor
1Safety
1Severity of Illness Index
1Tesofensine
1Time Factors
1pramipexole extended release
1pramipexole‐extended release
1switch trial
1treatment

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/USA/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i -k "Laurence Salin" 
HfdIndexSelect -h $EXPLOR_AREA/Data/USA/Analysis/Author.i  \
                -Sk "Laurence Salin" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/USA/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    USA
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Laurence Salin
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024